Implementation of Pharmacist Driven Gabapentinoid Titration for Diabetic Peripheral Neuropathy in a Primary Care Setting.

Emma Eibye, Julie M Waldfogel, Patricia A Ross, Callan Banks, Joshua Chou, Katharine Russo, Jessica Merrey
{"title":"Implementation of Pharmacist Driven Gabapentinoid Titration for Diabetic Peripheral Neuropathy in a Primary Care Setting.","authors":"Emma Eibye, Julie M Waldfogel, Patricia A Ross, Callan Banks, Joshua Chou, Katharine Russo, Jessica Merrey","doi":"10.1080/15360288.2024.2421527","DOIUrl":null,"url":null,"abstract":"<p><p>Previous studies suggest that patients with diabetic peripheral neuropathy (DPN) frequently do not receive the minimum effective doses of a gabapentinoid according to guidance from national organizations. There is opportunity to assess the implementation of pharmacist intervention for patients not meeting minimum effective gabapentinoid dosing for DPN. This prospective, single site quality improvement project was conducted at a primary care clinic and included patients with DPN prescribed a gabapentinoid by their primary care provider (PCP) at a dose lower than minimum effective dosing. Pharmacists assessed patient-reported pain ratings, adverse effects, and renal function for appropriate dosing and titrated to minimum effective dosing based on clinical judgment. All patients that were followed through week 13 had a clinically significant improvement in pain. No patients met a 50% reduction in patient-reported pain rating scales on guidance-directed minimum effective dosing. No patients were able to meet the minimum effective dose. The majority of patients declined pharmacist services due to neuropathy being controlled on the current gabapentinoid dose. This study supports the ability for pharmacists to assess patient specific factors for adequate dosing, titration, and deprescribing recommendations for analgesic medications in diabetic peripheral neuropathy.</p>","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"1-8"},"PeriodicalIF":0.9000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pain & Palliative Care Pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/15360288.2024.2421527","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Previous studies suggest that patients with diabetic peripheral neuropathy (DPN) frequently do not receive the minimum effective doses of a gabapentinoid according to guidance from national organizations. There is opportunity to assess the implementation of pharmacist intervention for patients not meeting minimum effective gabapentinoid dosing for DPN. This prospective, single site quality improvement project was conducted at a primary care clinic and included patients with DPN prescribed a gabapentinoid by their primary care provider (PCP) at a dose lower than minimum effective dosing. Pharmacists assessed patient-reported pain ratings, adverse effects, and renal function for appropriate dosing and titrated to minimum effective dosing based on clinical judgment. All patients that were followed through week 13 had a clinically significant improvement in pain. No patients met a 50% reduction in patient-reported pain rating scales on guidance-directed minimum effective dosing. No patients were able to meet the minimum effective dose. The majority of patients declined pharmacist services due to neuropathy being controlled on the current gabapentinoid dose. This study supports the ability for pharmacists to assess patient specific factors for adequate dosing, titration, and deprescribing recommendations for analgesic medications in diabetic peripheral neuropathy.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在基层医疗机构实施由药剂师驱动的加巴喷丁胺滴定法治疗糖尿病周围神经病变。
以往的研究表明,糖尿病周围神经病变(DPN)患者经常无法按照国家组织的指导获得最小有效剂量的加巴喷丁胺。现在有机会评估药剂师对未达到加巴喷丁诺类药物治疗 DPN 最低有效剂量的患者进行干预的实施情况。该前瞻性单点质量改进项目在一家初级保健诊所开展,包括初级保健提供者(PCP)开出的剂量低于最低有效剂量的加巴喷丁类药物的 DPN 患者。药剂师对患者报告的疼痛评分、不良反应和肾功能进行评估,以确定合适的剂量,并根据临床判断将剂量调整到最低有效剂量。所有随访至第 13 周的患者的疼痛均有明显的临床改善。在指导性最低有效剂量下,没有患者的患者报告疼痛评分量表达到减少 50%的要求。没有患者能够达到最低有效剂量。大多数患者拒绝了药剂师的服务,原因是目前的加巴喷丁诺剂量可以控制神经病变。这项研究证明,药剂师有能力评估患者的具体因素,以便为糖尿病周围神经病变患者提供适当的镇痛药物剂量、滴定和停药建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.60
自引率
9.10%
发文量
40
期刊最新文献
Implementation of Pharmacist Driven Gabapentinoid Titration for Diabetic Peripheral Neuropathy in a Primary Care Setting. Longitudinal Evaluation of the Risk Index for Overdose or Serious Opioid-Induced Respiratory Depression in Patients with Cancer. Evaluating the Impact of Buprenorphine on Depressive Symptoms Among Veterans with Chronic Pain. Cannabis-Based Treatments for Fibromyalgia: Implications for the Philippines' Medical Cannabis Legalization. Pain Neuroscience Education: Teaching People About Pain.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1